Quanta Receives CE Mark for its Advanced Haemodialysis System SC+

ALCESTER, England, January 6, 2015 /PRNewswire/ --

Quanta Fluid Solutions Ltd ("Quanta" or the "Company"), a pioneering developer of advanced haemodialysis systems, announces it has received the CE mark for SC+, its portable, cartridge-based haemodialysis system.

SC+ is designed to bring flexibility to dialysis patients and physicians by supporting all treatment regimens, from nurse-assisted care and patient self-care in-centre to home haemodialysis. SC+ is the only portable, compact haemodialysis system with the clinical efficacy and high flow rates of traditional in-centre machines. The technology behind SC+ is based on an innovative and unique design that incorporates all fluid management activities onto a single-use disposable cartridge.

Quanta is also pleased to announce that it has raised additional funds expanding its recent investment round to a total of £29 million. The round was led by new investor ALIAD, the venture capital investment vehicle of Air Liquide SA (Paris: AI), and included participation by additional new investors Seventure Partners and Kuwait Life Sciences Company, as well as existing investors Wellington Partners, Seroba Kernel, NBGI Ventures, b-to-v Partners and IMI plc (LSE: IMI).

John E. Milad, Chief Executive Officer of Quanta, said: "This is an exciting time for Quanta.  Obtaining the CE mark for SC+ is a major milestone forus and is a testament to the ingenuity and engineering excellence of our team. SC+ is a revolutionary dialysis system based around a novel single-use disposable cartridge. Our system will provide meaningful benefits to patients and healthcare providers in terms of ease-of-use, flexibility and performance. 2014 was a transformational year for Quanta, and we are now strongly positioned to introduce SC+ for clinical use in 2015."

Professor John Agar,  a practicing clinical nephrologist, Clinical Conjoint Professor of Medicine at Deakin University School of Medicine at the Geelong Hospital, Barwon Health and Member of Quanta's Medical Advisory Board, said: "Quanta's SC+ is the first real advance in dialysis system choice in a decade and a half. While small, light, and truly portable, it is still at its heart, a single pass dialysis system providing efficient and comparable dialysis to current technologies. SC+ has the benefit of transferability from centre to home, and from home to centre, which gives valuable and flexible treatment options for physicians, patients and care givers. This is a truly game-changing technology."

About Quanta 

Quanta is developing advanced haemodialysis systems for use in the clinic and the home. The Company's cartridge-based solution SC+ is the only portable, compact haemodialysis system with the clinical efficacy and high flow rates of traditional machines. SC+ is designed to offer ease-of-use and flexibility, facilitating self-care and supporting dialysis patients across the entire continuum of care.

Quanta is privately owned and based in Alcester, UK. The Company was founded in 2008 as a spin out from the FTSE 100 engineering company IMI plc, with funding provided by a group of leading venture capital investors specialised in healthcare: NBGI Ventures, Wellington Partners, Seroba Kernel and b-to-v Partners, and more recently ALIAD, Seventure Partners and Kuwait Life Sciences Company.

Quanta is dedicated to creating a paradigm shift in renal care and to improving the lives of dialysis patients.

For more information please visit: http://www.quantafs.com.

About End Stage Renal Disease and Haemodialysis:  

Lifestyle choices, modern diet and increased life expectancy are all negatively impacting renal health across the globe and End Stage Renal Disease affects millions of patients worldwide. Haemodialysis is a life-saving treatment delivered to an estimated 2 million people globally-with this figure expected to double in the next decade.

At present, haemodialysis is primarily provided by specialist clinics and centres. However this means that the patient is not in control of when they can dialyse. It is clinically proven that more regular dialysis improves outcomes and quality of life for the patient, and a number of studies have shown that 30-40% of patients would be capable of performing self-dialysis.

Issues of patient benefit, cost and clinic capacity are driving the growth of home and self-care modalities of haemodialysis, but a major factor limiting the growth of self-care and home haemodialysis is the lack of convenient, portable and easy-to-use dialysis systems.  SC+ addresses these issues and puts the patient at the centre, allowing them to take greater control of their treatment.

For more information about Quanta, please contact: 
Quanta
John E. Milad,
Chief Executive Officer                      
T: +44-(0)1789-400043                                         
E: [email protected]

Consilium Strategic Communications           
Amber Bielecka / Mary-Jane Elliott / Matthew 
Neal / Lindsey Neville                       
T: +44-(0)203-709-5708
E:[email protected]

SOURCE Quanta